TRPM2 and obesity due to melanocortin 4 receptor deficiency: Experimental disease models have shown that preventing TRPM2 channel activation mitigates many conditions, including diabetes, obesity, hypertension, atherosclerosis, ischemia/reperfusion (I/R) injury, heart failure, and endothelial dysfunction [37,38] (Table 1).